RESUMEN
BACKGROUND: Electrospun fibers are a good candidate for the delivery of bioactive compounds in the food industry because of their advantages that include a tunable diameter, high porosity and a high specific surface area. In the present study, we fabricated gelatin/glycerol monolaurate (GML) microemulsion nanofibers by solubilizing GML in Tween-80 followed by mixing with gelatin solution for electrospinning. We hypothesized that the addition of GML microemulsions affects the properties of the gelatin solution and modifies the physical and antimicrobial properties of the resulting nanofibers. RESULTS: Both pure gelatin solution and gelatin/GML microemulsions showed shear-thinning behavior. However, electrospinnability was not affected by the addition of GML microemulsions. A significantly higher average diameter of nanofibers (1147 nm) with 5% GML was observed compared to the gelatin fiber diameter of 560 nm. Fourier transform infrared spectroscopy showed hydrogen bonding between gelatin molecules and GML microemulsions. Thermal analysis and X-ray diffraction indicated an amorphous structure of gelatin/GML microemulsion nanofibers, although a small amount of crystalline GML existed in the nanofibers with high GML content. Gelatin/GML microemulsion nanofibers showed high thermal stability and improved hydrophilicity. Nanofibers with 5% GML (weight with respect to nanofiber) (D64 nanofibers) showed effective antimicrobial activity against Escherichia coli and Staphylococcus aureus. CONCLUSION: Gelatin/GML microemulsion nanofibrous films demonstrate superhydrophilicity and fast dissolution properties as a result of the high surface-to-volume ratio, amorphous structure and improved hydrophilicity of the nanofiber surface. The results indicate the potential application of gelatin/GML microemulsion nanofibrous films as edible antimicrobial food packaging. © 2021 Society of Chemical Industry.
Asunto(s)
Antibacterianos/química , Antibacterianos/farmacología , Composición de Medicamentos/métodos , Lauratos/química , Lauratos/farmacocinética , Monoglicéridos/química , Monoglicéridos/farmacocinética , Escherichia coli , Gelatina/química , Nanofibras/química , Polisorbatos/química , Solubilidad , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/crecimiento & desarrolloRESUMEN
The human immunodeficiency virus epidemic affects millions of people worldwide. As women are more vulnerable to infection, female-controlled interventions can help control the spread of the disease significantly. Glycerol monolaurate (GML), an inexpensive and safe compound, has been shown to protect against simian immunodeficiency virus infection when applied vaginally. However, on account of its low aqueous solubility, fabrication of high-dose formulations of GML has proven difficult. We describe the development of a vaginal cream that could be loaded with up to 35% GML. Vaginal drug levels and safety of 3 formulations containing increasing concentrations of GML (5%w/w, 15%w/w, and 35%w/w) were tested in rhesus macaques after vaginal administration. GML concentration in the vaginal tissue increased as the drug concentration in the cream increased, with 35% GML cream resulting in tissue concentration of â¼0.5 mg/g, albeit with high interindividual variability. Compared with the vehicle control, none of the GML creams had any significant effect on the vaginal flora and cytokine (macrophage inflammatory protein 3α and interleukin 8) levels, suggesting that high-dose GML formulations do not induce local adverse effects. In summary, we describe the development of a highly loaded vaginal cream of GML, and vaginal drug levels and safety after local administration in macaques.
Asunto(s)
Antivirales/administración & dosificación , Antivirales/farmacocinética , Lauratos/administración & dosificación , Lauratos/farmacocinética , Monoglicéridos/administración & dosificación , Monoglicéridos/farmacocinética , Cremas, Espumas y Geles Vaginales/química , Administración Intravaginal , Animales , Antivirales/efectos adversos , Citocinas/análisis , Femenino , Infecciones por VIH/prevención & control , Humanos , Lauratos/efectos adversos , Macaca mulatta , Monoglicéridos/efectos adversos , Reología , Síndrome de Inmunodeficiencia Adquirida del Simio/prevención & control , Virus de la Inmunodeficiencia de los Simios/efectos de los fármacos , Vagina/efectos de los fármacos , Vagina/metabolismo , Vagina/microbiología , Cremas, Espumas y Geles Vaginales/efectos adversosRESUMEN
Thromboembolic diseases such as myocardial infarction, stroke, transient ischemic attacks, and pulmonary embolism are major causes of morbidity and mortality worldwide. Glycoprotein IIb/IIIa (GPIIb/IIIa) is the key receptor involved in platelet aggregation and is a validated target for therapeutic approaches and diagnostic imaging. The aim of this study was to develop and characterize a specific small-molecule tracer for PET imaging that binds with high affinity to GPIIb/IIIa receptors and has suitable pharmacokinetic properties to overcome limitations of previous approaches. Methods: Binding of 18F-GP1 to GPIIb/IIIa receptors was investigated in competition binding assays and autoradiography using a fresh cardiac thrombus from an explanted human heart. The clot-to-blood ratio for 18F-GP1 was investigated by an in vitro blood flow model. Biodistribution and thrombus detection was investigated in cynomolgus monkeys after insertion of a roughened catheter into either the vena cava or the aorta. Results:18F-GP1 is an 18F-labeled small molecule for PET imaging of thrombi. The half maximal inhibitory concentration of 18F-GP1 to GPIIb/IIIa was 20 nM. 18F-GP1 bound to thrombi with a mean clot-to-blood ratio of 95. Binding was specific and can be displaced by excess nonradioactive derivative. Binding was not affected by anticoagulants such as aspirin or heparin. 18F-GP1 showed rapid blood clearance and a low background after intravenous injection in cynomolgus monkeys. Small arterial, venous thrombi, thrombotic depositions on damaged endothelial surface, and small cerebral emboli were detected in vivo by PET imaging. Conclusions:18F-GP1 binds specifically with high affinity to the GPIIb/IIIa receptor involved in platelet aggregation. Because of its favorable preclinical characteristics, 18F-GP1 is currently being investigated in a human clinical study.
Asunto(s)
Glutamina/análogos & derivados , Lauratos/farmacocinética , Imagen Molecular/métodos , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/metabolismo , Tomografía de Emisión de Positrones/métodos , Trombosis/diagnóstico por imagen , Trombosis/metabolismo , Animales , Femenino , Radioisótopos de Flúor/química , Radioisótopos de Flúor/farmacocinética , Glutamina/farmacocinética , Humanos , Marcaje Isotópico/métodos , Macaca fascicularis , Radiofármacos/síntesis química , Radiofármacos/farmacocinética , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
The aim of this study was to prepare riboflavin laurate (RFL) nanosuspensions as an intramuscular injection for long-term riboflavin supplementation. Stable RFL nanosuspensions were obtained by injecting RFL/poloxamer solution in N,N-dimethyl formamide into a trehalose solution. Long soft nanostructures initially appeared and then tube-like rigid nanostructures were obtained after removal of solvents according to the transmission electron microscopic images. The nanosuspensions had narrow size distribution and the mean size was about 300 nm. Molecular self-assembly of RFL may drive the formation of nanostructures. RFL formed a monolayer at the air/water interface and poloxamer 188 could insert into the monolayer. The nanosuspensions were intramuscularly injected into rats to provide long-term riboflavin supplementation for more than 30 days in light of body weight, food intake, and urinary riboflavin. The nanosuspensions were also used to resist the riboflavin deficiency induced by methotrexate chemotherapy. RFL nanosuspensions are a promising nanomedicine for long-term riboflavin supplementation.
Asunto(s)
Lauratos/administración & dosificación , Riboflavina/administración & dosificación , Complejo Vitamínico B/administración & dosificación , Animales , Suplementos Dietéticos , Inyecciones Intramusculares , Lauratos/farmacocinética , Lauratos/orina , Masculino , Metotrexato , Nanoestructuras/administración & dosificación , Úlceras Bucales/inducido químicamente , Úlceras Bucales/prevención & control , Ratas , Ratas Sprague-Dawley , Riboflavina/farmacocinética , Riboflavina/orina , Deficiencia de Riboflavina/inducido químicamente , Deficiencia de Riboflavina/prevención & control , Suspensiones , Complejo Vitamínico B/farmacocinética , Complejo Vitamínico B/orinaRESUMEN
Beta-Cryptoxanthin (beta-CX), a provitaminic carotenoid of potential interest for health, is found principally in Citrus fruit in both free and esterified forms. Little is known about the intestinal absorption of beta-CX especially with regard to the esterified forms. The aim of this study was to evaluate the absorption of free and esterified beta-CX using simulated digestion coupled with the Caco-2 model. Bioaccessibility was investigated by measuring the transfer of carotenoids from different citrus juices into micelles using an in vitro digestion system. Then, carotenoid uptake was evaluated by adding carotenoid-rich micelles (from the in vitro digestion) or synthetic micelles (made from synthetic lipids and carotenoids purified from citrus juice) to human intestinal cells (Caco-2 TC7 clone). Our results showed that beta-cryptoxanthin esters (beta-CXE) were partially hydrolysed during the in vitro digestion. The bioaccessibility of free beta-CX measured was significantly higher (40 (SD 1.05) %) than that of beta-carotene (30 (SD 1.9) %) and beta-CXE (16 (SD 1.5) %). In the same way, the incorporation of free beta-CX (27 (SD 1.01) %) into synthetic micelles exceeded (P<0.05) that of beta-carotene (10 (SD 0.7) %) and beta-CXE (8.8 (SD 0.4) %). In the case of micelles from in vitro digestion, the uptake of beta-carotene, free beta-CX and beta-CXE forms by Caco-2 cells was 14.3 (SD 1.8), 3.9 (SD 1.3), and 0.7 (SD 0.08) % respectively. These results showed a preferential uptake by Caco-2 cells of beta-carotene and free beta-CX compared with the two esters of beta-CX.
Asunto(s)
Anticarcinógenos/farmacocinética , Bebidas , Citrus/química , Digestión/fisiología , Xantófilas/farmacocinética , Disponibilidad Biológica , Células CACO-2 , Citrus sinensis , Criptoxantinas , Humanos , Absorción Intestinal/fisiología , Lauratos/farmacocinética , Micelas , Modelos Biológicos , Miristatos/farmacocinética , beta Caroteno/farmacocinéticaRESUMEN
Percutaneous delivery of NSAIDs has advantages of avoiding hepatic first pass effect and delivering the drug for extended period of time at a sustained, concentrated level at the inflammation site that mainly acts at the joint and the related regions. To develop the new topical formulations of pranoprofen that have suitable bioadhesion, the gel was formulated using hydroxypropyl methylcellulose (HPMC) and poloxamer 407. The effects of temperature on drug release was performed at 32 degrees C, 37 degrees C and 42 degrees C according to drug concentration of 0.04%, 0.08%, 0.12%, 0.16%, and 0.2% (w/w) using synthetic cellulose membrane at 37+/-0.5 degrees C. The increase of temperature showed the increased drug release. The activation energy (Ea), which were calculated from the slope of lop P versus 1000/T plots was 11.22 kcal/ mol for 0.04%, 10.79 kcal/mol for 0.08%, 10.41 kcal/mol for 0.12% and 8.88 kcal/mol for 0.16% loading dose from the pranoprofen gel. To increase the drug permeation, some kinds of penetration enhancers such as the ethylene glycols, the propylene glycols, the glycerides, the non-ionic surfactants and the fatty acids were incorporated in the gel formulation. Among the various enhancers used, propylene glycol mono laurate showed the highest enhancing effects with the enhancement factor of 2.74. The results of this study suggest that development of topical gel formulation of pranoprofen containing an enhancer is feasible.
Asunto(s)
Benzopiranos/farmacocinética , Geles/química , Propionatos/farmacocinética , Absorción Cutánea , Piel/metabolismo , Adhesivos/química , Administración Cutánea , Algoritmos , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacocinética , Benzopiranos/administración & dosificación , Benzopiranos/química , Transporte Biológico , Temperatura Corporal , Difusión , Derivados de la Hipromelosa , Lauratos/química , Lauratos/farmacocinética , Masculino , Metilcelulosa/análogos & derivados , Metilcelulosa/química , Permeabilidad , Poloxámero/química , Propionatos/administración & dosificación , Propionatos/química , Glicoles de Propileno/química , Glicoles de Propileno/farmacocinética , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Solubilidad , Tensión Superficial , Tecnología Farmacéutica/métodos , Temperatura , ViscosidadRESUMEN
The existence of a novel cubic liquid crystalline phase is described within the pseudo-ternary system comprising lauric acid, monolaurin, and simulated endogenous intestinal fluid (SEIF). This phase behaviour has been characterized using cross-polarizing light microscopy (CPLM), and the structure of the cubic phase identified by small angle X-ray scattering (SAXS). The presence of the cubic phase was found to be temperature sensitive within the 20-37 degrees C range making it putative material for in situ gelation purposes. The cubic phase was shown to have a high capacity to solubilise a model poorly water-soluble drug, cinnarizine, and initial in vitro release data highlight the potential of this phase to provide sustained release. Absorption of cinnarizine from the cubic phase was studied in an unconscious rat model via duodenal administration and blood sampling via the carotid artery. The rate of absorption was significantly reduced when compared to a simple suspension formulation, a likely combination of retarded erosion of the cubic phase together with hindered drug release from the cubic matrix. The results of this study suggest that this cubic phase may potentially be of benefit in the delivery of poorly water-soluble compounds due to its high loading capacity and potential for sustained release. The ability to manipulate this system using temperature may warrant further interest in delivery applications via other routes of administration.
Asunto(s)
Química Farmacéutica/tendencias , Portadores de Fármacos/farmacocinética , Glicéridos/farmacocinética , Interacciones Hidrofóbicas e Hidrofílicas , Lauratos/farmacocinética , Ácidos Láuricos/farmacocinética , Animales , Australia , Cateterismo/métodos , Química Farmacéutica/métodos , Cinarizina/administración & dosificación , Cinarizina/sangre , Cinarizina/farmacocinética , Cristalización , Preparaciones de Acción Retardada , Portadores de Fármacos/química , Evaluación Preclínica de Medicamentos/métodos , Duodeno/efectos de los fármacos , Glicéridos/química , Secreciones Intestinales/química , Lauratos/química , Ácidos Láuricos/química , Masculino , Microscopía de Polarización/métodos , Monoglicéridos , Ratas , Ratas Sprague-Dawley , Suspensiones/administración & dosificación , Suspensiones/farmacocinéticaRESUMEN
For monitoring low-density lipoprotein receptors (LDLr) in tumors and in livers of patients with familial hypercholesterolemia (FH) treated with gene therapy, a series of tricarbocyanine cholesteryl laurates were synthesized with the cholesteryl laurate moiety serving as the lipid-chelating anchor for low-density lipoprotein (LDL). One of these conjugates, TCL17, was successfully used to label LDL to give a new NIRF, TCL17-LDL. Ex vivo biological studies on an LDLr overexpressing tumor model, human hepatoblastoma G(2) (HepG(2)), confirmed that this NIRF were internalized selectively by the tumor and detected with high sensitivity by a low-temperature 3-D redox scanner.
Asunto(s)
Ésteres del Colesterol/metabolismo , LDL-Colesterol/metabolismo , Colorantes Fluorescentes/metabolismo , Hepatoblastoma/metabolismo , Hiperlipoproteinemia Tipo II/metabolismo , Lauratos/metabolismo , Neoplasias Hepáticas/metabolismo , Receptores de LDL/metabolismo , Animales , Carbocianinas/síntesis química , Carbocianinas/química , Carbocianinas/farmacocinética , Ésteres del Colesterol/química , Ésteres del Colesterol/farmacocinética , LDL-Colesterol/síntesis química , LDL-Colesterol/química , LDL-Colesterol/farmacocinética , Colorantes Fluorescentes/síntesis química , Colorantes Fluorescentes/química , Colorantes Fluorescentes/farmacocinética , Terapia Genética , Hepatoblastoma/tratamiento farmacológico , Humanos , Hiperlipoproteinemia Tipo II/terapia , Imagenología Tridimensional , Lauratos/síntesis química , Lauratos/química , Lauratos/farmacocinética , Neoplasias Hepáticas/terapia , Ratones , Espectroscopía Infrarroja CortaRESUMEN
An ethyl laurate-based microemulsion system with Tween 80 as surfactant, propylene glycol and ethanol as cosolvents was developed for intranasal delivery of diazepam. Phase behavior and solubilization capacity of the microemulsion system were characterized and in vivo nasal absorption of diazepam from microemulsion formulations was investigated in rabbits. A single isotropic region, which is considered as a bicontinuous microemulsion, was found in the pseudo-ternary phase diagrams developed at various Tween 80: propylene glycol: ethanol ratios. With the increase of Tween 80 concentration, the microemulsion region area, microemulsion viscosity, and the amount of H(2)O and ethyl laurate solubilized into the microemulsion system increased; however, the increase of ethanol percentage produced opposite effects. Diazepam, a practically water-insoluble drug, displayed a high solubility of 41 mg/ml in a microemulsion consisting of 15% ethyl laurate, 15% H(2)O, and 70% (w/w) surfactant/cosurfactant (Tween 80:propylene glycol:ethanol at 1:1:1 weight ratio). Nasal absorption of diazepam from this microemulsion was found to be fairly rapid. At 2 mg/kg dose, the maximum drug plasma concentration was arrived within 2-3 min, and the bioavailability (0-2 h) after nasal spray compared with intravenous injection was about 50%. These results suggest that this ethyl laurate-based microemulsion may be a useful approach for the rapid-onset delivery of diazepam during the emergency treatment of status epilepticus.
Asunto(s)
Anticonvulsivantes/administración & dosificación , Diazepam/administración & dosificación , Lauratos/administración & dosificación , Administración Intranasal , Animales , Anticonvulsivantes/farmacocinética , Disponibilidad Biológica , Química Farmacéutica , Diazepam/farmacocinética , Emulsiones , Lauratos/farmacocinética , Conejos , Tensoactivos/administración & dosificación , Tensoactivos/farmacocinéticaRESUMEN
Intestinal absorption of 125I-labelled lauryl thyrotropin-releasing hormone (Lau-TRH), a novel lipophilic derivative of TRH, was examined by rat in-situ closed intestinal loops. At a dose of 1 mumol per rat into the small intestine, a significant increase in percent of dose in plasma radioactivity of Lau-TRH was observed in comparison with that of TRH. A dose-dependent decrease in percent of dose in plasma radioactivity of TRH was noted, suggesting a saturable process of TRH transport. In contrast, the percent of dose in plasma radioactivity of Lau-TRH increased with increasing dose of Lau-TRH. The stability of TRH and Lau-TRH was studied in plasma and rat small intestinal homogenates. Lau-TRH was more stable than TRH in rat plasma. These results suggest that chemical modification of TRH with lauric acid may not only increase the lipophilicity of TRH but also reduce the degradation of TRH, resulting in the increased plasma radioactivity of TRH. On the other hand, Lau-TRH was gradually converted to TRH in the intestinal mucosal homogenate. These findings indicate that chemical modification of TRH with lauric acid might be a useful approach for improving the intestinal absorption of this peptide.